SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Kilitch Drugs (India) informs about certificate

17 Jul 2023 Evaluate

Pursuant to Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulation, 2018, Kilitch Drugs (India) has informed that it enclosed the Certificate received from Link Intime India, the Registrar and Share Transfer Agent of the Company for the quarter ended 30th June, 2023.

The above information is a part of company’s filings submitted to BSE.

Kilitch Drugs(India) Share Price

150.75 -9.20 (-5.75%)
24-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1619.95
Dr. Reddys Lab 1315.85
Cipla 1294.75
Zydus Lifesciences 927.15
Lupin 2296.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×